Analysis by AlgoNomics reveals that Anticalins have an immunogenicity level comparable to the wild-type human lipocalin
Pieris AG and AlgoNomics NV announced that AlgoNomics' proprietary platform for T-cell epitope identification, Epibase®, revealed that Pieris' human binding proteins Anticalins® intrinsically have an immunogenicity level comparable to the wild-type human lipocalin, as witnessed by a comparable number and promiscuity of the T-cell epitopes identified.
According to the company, Epibase® analysis supports Pieris in the selection and optimization of Anticalins® with favorable properties including the lowest possible immunogenicity both in their internal projects and in collaborative projects with its partners.
"Pieris purposely selected human lipocalin scaffolds for therapeutic use because of their intrinsic properties. The chosen human lipocalins are small, non-glycosylated, highly stable monomeric binding proteins present in significant amounts in blood and other bodily fluids. Anticalins® are therefore expected to exhibit a low immunogenicity potential upon repeated parenteral use", says Dr. Andreas Hohlbaum, Pieris' Director of Science and Preclinical Development.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Rhenovia files patents for new treatment of Huntington’s disease based on its biosimulation platform
Agilent Technologies, Human Metabolome Technologies collaborate on metabolomics solution to speed disease and drug research
Applying quantitative proteomics to tumor marker discovery
Novel insights in MET-proto-oncogene might lead to optimizing cancer treatment - MET inhibitors could have a double-edged effect on tumors
Mosaiques and U.S. FDA sign contract for collaboration in discovery and validation of biomarkers for assessment of drug toxicity
Danny_Glover
LEUKOCARE has been granted both ISO 9001 and ISO 13485 certification
Alligator Bioscience enters into research and option agreement with BioInvent to jointly develop Antibody-based therapeutics
Seegene Receives Approval from Health Canada for Its Respiratory Virus Multi-Pathogen Detection Tests
MDxHealth establishes US CLIA laboratory in Irvine, CA, and makes key hires to expand US team
